Skip to main content

Antonino Catanzaro, MD

Antonio Catanzaro

Professor of Medicine
Previously Director, Tuberculosis Control
Division of Pulmonary, Critical Care, and Sleep Medicine
UC San Diego School of Medicine
San Diego, California

What data and experience have been accumulated over time that explain why NTM pulmonary infection has now become recognized as a significant disease problem with a formidable disease burden and unmet therapeutic needs?

What data and experience have been accumulated over time that explain why NTM pulmonary infection has now become recognized as a significant disease problem with a formidable disease burden and unmet therapeutic needs?

Antonio Catanzaro, MD

What is the epidemiology of MAC lung disease and why is it important that clinicians are aware of the specific geographic and prevalence patterns that characterize and account for our increased recognition of NTM disease?

What is the epidemiology of MAC lung disease and why is it important that clinicians are aware of the specific geographic and prevalence patterns that characterize and account for our increased recognition of NTM disease?

Antonio Catanzaro, MD

What do MAC lung patients look like? How do they present and what are both the typical and unusual clinical signatures that suggest need for further evaluation, including microbial confirmation?

What do MAC lung patients look like? How do they present and what are both the typical and unusual clinical signatures that suggest need for further evaluation, including microbial confirmation?

Antonio Catanzaro, MD

What are the sequential steps—radiographic assessment, bronchoscopy, and microbial sampling—that constitute the workup of individuals suspected of NTM pulmonary infection? What are the pitfalls of sputum sampling and how do we overcome them?

What are the sequential steps—radiographic assessment, bronchoscopy, and microbial sampling—that constitute the workup of individuals suspected of NTM pulmonary infection? What are the pitfalls of sputum sampling and how do we overcome them?

Antonio Catanzaro, MD

Can you take us through microbiological testing for NTM and MAC lung disease, emphasizing the specific tests required to confirm diagnosis and specific causative pathogens; and when such testing should be continued throughout treatment?

Can you take us through microbiological testing for NTM and MAC lung disease, emphasizing the specific tests required to confirm diagnosis and specific causative pathogens; and when such testing should be continued throughout treatment?

Antonio Catanzaro, MD

What clinical, microbiological, and radiographic triggers do you need in an individual with MAC lung infection to embark on anti-infective treatment? How often do you see patients with NTM disease and how do you make the decision to treat or monitor?

What clinical, microbiological, and radiographic triggers do you need in an individual with MAC lung infection to embark on anti-infective treatment? How often do you see patients with NTM disease and how do you make the decision to treat or monitor?

Antonio Catanzaro, MD

Given the tolerability issues associated with the currently applicable—although last issued in 2007—treatment guidelines for NTM lung disease, how do you sequence and titrate therapy in patients you commit to anti-infective treatment?

Given the tolerability issues associated with the currently applicable—although last issued in 2007—treatment guidelines for NTM lung disease, how do you sequence and titrate therapy in patients you commit to anti-infective treatment?

Antonio Catanzaro, MD

How long should treatment be continued with three-drug oral therapy before the regimen is considered to be successful or whether lack of culture conversion suggests intensification with amikacin is indicated?

How long should treatment be continued with three-drug oral therapy before the regimen is considered to be successful or whether lack of culture conversion suggests intensification with amikacin is indicated?

Antonio Catanzaro, MD

How do you navigate the multiple branch points of guideline-endorsed therapy for MAC lung function? And how do you make modifications in dosing frequency, and in what patients do you consider such changes?

How do you navigate the multiple branch points of guideline-endorsed therapy for MAC lung function? And how do you make modifications in dosing frequency, and in what patients do you consider such changes?

Antonio Catanzaro, MD

When does the accumulated clinical data—i.e. cavitation, symptom severity, etc.—support the use for amikacin, either systemically or with the inhaled liposome suspension, for MAC lung disease?

When does the accumulated clinical data—i.e. cavitation, symptom severity, etc.—support the use for amikacin, either systemically or with the inhaled liposome suspension, for MAC lung disease?

Antonio Catanzaro, MD

Can you summarize your perspective on advances in the treatment of MAC lung disease and your position on amikacin liposome inhalation suspension in patients who require intensification beyond three-drug oral treatment?

Can you summarize your perspective on advances in the treatment of MAC lung disease and your position on amikacin liposome inhalation suspension in patients who require intensification beyond three-drug oral treatment?

Antonio Catanzaro, MD

Given the complex clinical decision tree for NTM lung disease, what is your best counsel for how to optimize clinical outcomes across the severity range for this increasingly recognized pulmonary infection?

Given the complex clinical decision tree for NTM lung disease, what is your best counsel for how to optimize clinical outcomes across the severity range for this increasingly recognized pulmonary infection?

Antonio Catanzaro, MD